Purpose of Study
The primary objective is to understand the role of antitachycardia pacing (ATP) in primary prevention patients indicated for ICD therapy. The incidence of all-cause shocks in subjects programmed with shocks only will be compared with subjects programmed to standard therapy (ATP and shock) to assess equivalency.
Boston Scientific transvenous ICD implanted because of 1) prior MI and left ventricular ejection fraction less than or equal to 30% OR 2) Ischemic or non-ischemic cardiomyopathy and LVEF < 35%, and NYHA class II or III
Duration of Participation
Approximately 5 years
Contact Name: Lindsay Risk
Contact Phone: 515-633-3847
Contact Email: email@example.com